| ORIGINAL ARTICLE |
|
| Year : 2013 | Volume
: 19
| Issue : 4 | Page : 430-436 |
|
|
Promoter variants in interleukin-6 and tumor necrosis factor alpha and risk of coronary artery disease in a population from Western India
Aparna A Bhanushali, BR Das
Research and Development, Super Religare Laboratories Ltd., Goregaon West, Mumbai, Maharashtra, India
Correspondence Address:
B R Das
Research and Development, SRL Ltd., Prime Square Building, Plot No. 1, S. V. Road, Goregaon West, Mumbai - 400 062, Maharashtra
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/0971-6866.124371
|
|
|
Introduction: A central component of the atherosclerotic process is inflammation. Single nucleotide polymorphisms (SNPs) present in the promoter region of various cytokines can lead to altered levels of the transcript and a state of low-grade inflammation exacerbating the risk of coronary artery disease (CAD). The present work tries to understand the role of permissive promoter variants in the interleukin-6 gene (IL-6-174G/C) and the tumor necrosis factor alpha (TNFα-308G/A) in the causation of CAD and also dyslipidemia.
Materials and Methods: Genotyping was conducted on 100 cases of CAD and 150 controls by the allele termination assay SNaPshot. Biochemical parameters were determined by routine enzymatic endpoint methods. The results were analyzed by appropriate statistical methods.
Results: No differences in the minor allele frequency IL-6-174G/C SNP were seen between cases and controls (0.13 vs. 0.12). The differences in the allele frequency of TNFα-308A between cases (6%) and controls (2%) have led to an odds ratio, 3.370; 95% confidence interval, 1.039-11.543; P=0.033 in the univariate analysis. In the final logistic regression analysis, however none of the variants were associated with an increased risk of CAD.
Conclusions: In summary, no association of the permissive promoter variants in the IL-6 gene and the TNFα gene were seen with an increased CAD risk. These and other studies highlight the importance of doing population specific studies. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
